Innovative and adaptive strategies for new drug development are needed to maximize the potential of cell and gene therapies. CRA’s Lev Gerlovin with co-authors Walter Colasante and Pascale Diesel explain in this Cell and Gene article. Click here to read the article.
Assessing the economic case for Alzheimer’s disease policy prioritisation
The analysis has highlighted specific areas where more urgent action is needed, specifically: Accelerating diagnosing patients at scale; Supporting expansion...